# Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

> **NCT00694304** · PHASE3 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 535 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Vortioxetine (Lu AA21004)

## Key facts

- **NCT ID:** NCT00694304
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2010-03
- **Final completion:** 2010-04
- **Target enrollment:** 535 (ACTUAL)
- **Last updated:** 2014-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00694304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00694304, "Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00694304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*